Expert Explains Potential Long-term Impact of Yescarta CAR-T Cell Therapy For Patients with Lymphoma
Dr. Caron A. Jacobson discusses the potential long-term impact of Yescarta for patients with relapsed or refractory indolent non-Hodgkin lymphoma and how it could turn an incurable disease into something curable.
